Accelerating the Development of a Universal Influenza Vaccine: A Report from the Sabin-Aspen Vaccine Science and Policy Group

The Sabin-Aspen Vaccine Science & Policy Group convened in 2018 to explore challenges and opportunities to develop a universal influenza vaccine. The group’s recommendations on how to overcome the scientific, financial and organizational barriers to developing a vaccine are synthesized in the report Accelerating the Development of a Universal Influenza Vaccine.

The burden of pneumococcal disease in older children and adults in Latin America and the Caribbean

Streptococcus pneumoniae remains an important cause of pneumonia and invasive bacterial disease, primarily meningitis and sepsis. The greatest burden of disease occurs in low-and middle-income countries, and the risk of serious pneumococcal disease peaks at the extreme ages of life. Young children are at highest risk, but older adults and people with immuno-compromising conditions also suffer high rates of pneumococcal disease.

Pages